We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.47B
AUM Growth
-$458M
Cap. Flow
+$119M
Cap. Flow %
2.65%
Top 10 Hldgs %
43.81%
Holding
163
New
19
Increased
16
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$65.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$64M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$58.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$56.3M
5
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$43.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$65.4M
2
XLRN
Acceleron Pharma
XLRN
+$52.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$38.8M
4
SEER icon
Seer Inc
SEER
+$28.8M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82.57%
2 Miscellaneous 9.02%
3 Consumer Discretionary 6.51%
4 Financials 0.67%
5 Consumer Staples 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTCR
126
DELISTED
Metacrine, Inc. Common Stock
MTCR
$3.17M 0.07%
924,898
– –
KNTE
127
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.88M 0.06%
125,000
– –
HIPO icon
128
Hippo Holdings
HIPO
$859M
$2.81M 0.06%
+24,000
New +$4.21M
LITS
129
Lite Strategy Inc
LITS
$37.1M
$2.76M 0.06%
50,000
– –
KLDO
130
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$2.73M 0.06%
500,500
– –
CRVS icon
131
Corvus Pharmaceuticals
CRVS
$1.09B
$2.42M 0.05%
+500,000
New +$1.48M
KDNY
132
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.3M 0.05%
180,500
– –
CGEM icon
133
Cullinan Oncology
CGEM
$1.32B
$2.26M 0.05%
100,000
– –
KA
134
DELISTED
Kineta, Inc. Common Stock
KA
$2.24M 0.05%
31,056
– –
AXLA
135
DELISTED
Axcella Health Inc. Common Stock
AXLA
$2.12M 0.05%
28,500
– –
AVTR icon
136
Avantor
AVTR
$10.4B
$2.04M 0.05%
+50,000
New +$1.95M
AMYT
137
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$1.81M 0.04%
+150,480
New +$1.7M
SGTX
138
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$1.56M 0.03%
21,231
– –
IRWD icon
139
Ironwood Pharmaceuticals
IRWD
$671M
$1.44M 0.03%
110,532
– –
LVTX
140
DELISTED
LAVA Therapeutics
LVTX
$1.18M 0.03%
200,000
– –
RIGL icon
141
Rigel Pharmaceuticals
RIGL
$829M
$1.17M 0.03%
32,110
– –
SURF
142
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$757K 0.02%
100,000
– –
OPTU
143
Optimum Communications Inc
OPTU
$377M
$559K 0.01%
+27,000
New +$787K
CDTX
144
DELISTED
Cidara Therapeutics
CDTX
$503K 0.01%
11,234
– –
ATXS
145
DELISTED
Astria Therapeutics
ATXS
$295K 0.01%
+33,333
New +$319K
EQT icon
146
EQT Corp
EQT
$33.2B
$198K ﹤0.01%
+9,678
New +$187K
AGL icon
147
Agilon Health
AGL
$1.55B
– –
-12,000
Closed -$12.2M
ALDX icon
148
Aldeyra Therapeutics
ALDX
$82.6M
– –
-431,894
Closed -$4.89M
CAR icon
149
Avis
CAR
$4.19B
– –
-300,000
Closed -$23.4M
DLO icon
150
dLocal
DLO
$4.25B
– –
-295,000
Closed -$15.5M
3 4 5
6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2021 Portfolio in Review

As of Q3 2021, Artal Group held 163 positions worth $4.47B, down 9.3% from $4.93B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q3 2021 filing shows 19 new, 16 increased, 16 reduced and 17 closed positions. Its largest new stake was Erasca: 3,172,221 shares worth $67.3M. The largest sale was BeOne Medicines Ltd, an estimated $65.4M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q3 2021 buy was Erasca: 3,172,221 shares worth $67.3M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $56.3M increase.
  • Artal Group's biggest Q3 2021 reduction was BeOne Medicines Ltd, cutting an estimated $65.4M.
  • Artal Group fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021, selling an estimated $38.8M.
  • Artal Group's ten largest holdings make up 44% of its $4.47B portfolio in Q3 2021.
  • Artal Group opened 19 new positions and closed 17 in Q3 2021.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $4.47B.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.